Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add filters








Language
Year range
1.
Rev. chil. reumatol ; 26(4): 290-294, 2010. tab, ilus
Article in Spanish | LILACS | ID: lil-574190

ABSTRACT

Presentamos un paciente con Lupus Eritematoso Sistémico (LES) tratado previamente con Rituximab y Micofenolato Mofetilo que desarrolló una criptococosis meníngea. Los pacientes con LES presentan múltiples defectos en su sistema inmune (SI) que, sumados a los producidos por los tratamientos inmunosupresores, predisponen a infecciones, entre ellas, a las causadas por gérmenes oportunistas. La meningitis por criptococo es una rara y severa complicación en estos pacientes. Rituximab produce una serie de cambios en el SI actuando sobre los linfocitos B, mientras que micofenolato actúa tanto sobre las células T como B. Las alteraciones inmunológicas presentes en nuestro paciente serían producto de la sumatoria de efectos de ambas drogas que explicarían la infección por Criptococcus neoformans.


We presented a systemic lupus erythematosus (SLE) patient previously treated with rituximab and mycophenolate who developed cryptococcal meningitis. SLE patients have multiple defects in the immunity system in addition to the additive effects of immunosuppressive treatments, which predispose to opportunistic infections. Cryptococcal meningitis is a rare and severe complication in SLE patients. Rituximab produces a series of changes in the immune system by acting on B cells, while mycophenolate produces its actions by acting on T and B cells. The immunology system defects in our patient could be done because the additive effects of two drugs that could explain the Cryptococcus neoformans infection.


Subject(s)
Humans , Male , Adult , Immunosuppressive Agents/adverse effects , Antibodies, Monoclonal/adverse effects , Cryptococcosis/etiology , Lupus Erythematosus, Systemic/complications , Meningoencephalitis/etiology , Cryptococcus neoformans/isolation & purification , Immunologic Factors/adverse effects , Immunosuppression Therapy , B-Lymphocytes , B-Lymphocytes/immunology , T-Lymphocytes , T-Lymphocytes/immunology , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/drug therapy , Meningoencephalitis/microbiology , Opportunistic Infections
SELECTION OF CITATIONS
SEARCH DETAIL